

Saturday, 20 March 2004

08:30–10:30

SYMPOSIUM

Genetics – where are we?

469

INVITED

Genetics – where are we?

R.A. Eeles, Reader in Clinical Cancer Genetics, Institute of Cancer Research, Sutton, UK

A proportion of breast cancer cases arise due to a genetic predisposition; the exact proportion is unknown. A significant proportion of cases could occur due to low penetrance genes and this proportion will not be confirmed until such genes are discovered. Less than 5% is due to mutations in *BRCA1* and *BRCA2* although these genes are probably the most important of the highly penetrant breast cancer predisposition genes. Since their discovery, there are several pertinent issues in the *BRCA1/2* field.

What are the cancer risks from *BRCA1* and *BRCA2*? *BRCA1* and *BRCA2* predispose to breast and ovarian cancer. The lifetime penetrance figures in families with multiple cases of these cancers are 80–85% for breast cancer for both genes and 44–60% for *BRCA1* and 27% for *BRCA2* for ovarian cancer. These genes also predispose to other cancers: *BRCA2*: fallopian tube, prostate, pancreas, melanoma, head and neck, stomach and gall bladder cancer. *BRCA1*: colon, cervix, endometrium, pancreas and prostate cancer (but the latter to a lesser extent than *BRCA2*). There is debate about the penetrance in certain populations: it may be lower in the Ashkenazim (although one study refutes this) and mutations found in population-based single cases of breast cancer with no family history. This raises the possibility of modifier effects, either from environment and/or modifier genes.

Tumour genetic/pathological profiling: Breast cancers developing in *BRCA1* carriers have a different somatic genetic expression profile from non-carriers. It has also been reported that breast cancers from *BRCA1* carriers are more likely to be ER/PR negative and HER2 negative. Recently, positivity for cytokeratin expression has been described in *BRCA1* and this may be able to be used to determine which individuals with ER negative tumours should be offered germline *BRCA1* analysis in the future.

Issues in genetic counselling, testing and treatment: The issues surrounding penetrance are important for genetic counselling. At present, most testing, at least in Europe, occurs in cancer genetics clinics. The discoveries of specific pathological profiles for *BRCA1* tumours could alter this by bringing germline testing into clinical management of the primary tumour in the oncology clinic. There is an increased risk of contralateral breast cancer in germline *BRCA1/2* mutation carriers and some such women opt for bilateral mastectomy as their primary surgical management.

Is there a fingerprint of the presence of a germline *BRCA* mutation? We have found a set of about 50 genes that have differential expression in normal cells from *BRCA1* carriers after irradiation induced DNA damage. No difference is seen in unirradiated cells. This has implications for the use of DNA-damaging agents in screening and treatment of *BRCA1* carriers and could have application to distinguish pathogenic mutations from normal variants (polymorphisms).

470

INVITED

Use of oral contraceptives and risk of breast cancer in *BRCA1/2* mutation carriers

M. Rookus¹, R.M. Brohet¹, N. Andrieu², J. Chang-Claude³, M. Corbex⁴, N. Loman⁵, D.F. Easton⁶, D.E. Goldgar⁴. ¹The Netherlands Cancer Institute, Amsterdam, The Netherlands; ²Institut Gustave Roussy, Villejuif Cedex, France; ³German Cancer Research Center, Heidelberg, Germany; ⁴International Agency for Research on Cancer, Lyon, France; ⁵Lund University Hospital, Lund, Sweden; ⁶Strangeways Research Lab, Cambridge, UK

In the general population women who are currently using oral contraceptives are known to have a slightly increased (24%) risk of breast cancer. Stronger associations have been found for *BRCA1/2* mutations carriers. However, the sparse literature is inconsistent.

We investigated the association between use of oral contraceptives (OC) and risk of breast cancer among *BRCA1/2* mutation carriers in the International *BRCA1/2* Carrier Cohort Study (IBCCS study). Out of a sample of 1579 *BRCA1/2* mutation carriers we selected 202 cases who completed a standard mailed questionnaire within five years after diagnosis and matched them with 303 controls for a nested case-control analysis. Both groups were matched on age, cohort, and country group,

and analyses were adjusted for gene mutation, parity and prophylactic oophorectomy.

Women who currently used OC or women who had used OC in the past had a risk of breast cancer comparable with never users (Odds Ratio (OR)=1.22, 95% Confidence Interval (CI): 0.61–2.43 for current users, OR=1.05, 95% CI: 0.64–1.71 for ex users, respectively). Though a long duration of use was associated with an increased risk, this was not statistically significant (OR=1.87, 95% CI: 0.88–3.96 for OC use of 13 years or longer). Women who started OC use before age 20 had a similar risk as never users (OR=1.09, 95% CI: 0.69–1.75).

So far, no indication was found that the association between OC use and the risk of breast cancer among *BRCA1/2* mutation carriers strongly differs from what is known for the general population. However, with the higher background rates among *BRCA1/2* mutation carriers comparable relative risks imply higher absolute risks.

471

INVITED

First steps in the test process

W.J. Ormiston, P.A. Daly. St. James's Hospital PO Box 580, Department of Clinical Haematology&Onc., Dublin, Ireland

The testing process begins with identification of an at-risk individual and referral to a genetic clinic. Genetic counselling is an essential component of genetic testing and should include at least two individualized sessions. The first step in counselling is to assess the patient's concerns and motives for seeking help and to guarantee that where possible and appropriate his/her personal needs and priorities will be met. It is important for all health professionals to remember that the principal goal of cancer genetics care is to prevent death from cancer. Another important step is to compile an accurate family history. The family history or pedigree should include three generations and include all cases of cancer on both the paternal and maternal side. Unaffected family members need to be documented too as this enables an assessment of potential inheritance patterns. All malignancies should be confirmed through medical and/or death records, with relevant consent from relevant individuals within the family. During the counselling session risk assessment is undertaken and discussed. There are several risk models available for breast cancer that incorporate family history. Accurate analysis of the pedigree is essential when classifying individuals into high, moderate and low-risk groups.

Individuals at high risk of carrying a mutation on the basis of their family history can be offered genetic testing. Genetic testing is a two-stage process. The first step is to identify the altered gene in the family. The second is to offer genetic predictive testing to unaffected individuals in that family once the mutation has been found. Predictive testing is highly specific, and unaffected people in the family who are tested and who carry the pathogenic mutation are at increased risk of developing malignancy. The cancer risk of individuals who have a negative test for a known, deleterious mutation within their family is reduced to that of the normal population, and they should avail of screening and health promotion guidelines applicable to the general population. Individuals who harbour deleterious mutations in *BRCA1* and *BRCA2* need information regarding medical management so they can make informed choices. These management strategies include prophylactic surgical interventions chemoprevention and surveillance programmes. Uncertainty remains around interventions for this group, and thus up-to-date results of clinical trials and consensus views of expert panels are essential for women if they are to make informed choices.

472

INVITED

The issues for women following risk communication

P. Hopwood. Christie Hospital, Psychological Hospital, Manchester, UK

For the majority of women, risk communication significantly improves women's perceptions of their personal risk without an adverse effect on psychological well being, irrespective of wide variations in the provision of cancer genetic services. However, women who continue to overestimate their risk have higher levels of anxiety, and those who continue to underestimate may engage in sub optimal health care behaviour. Cancer worries are increased in women with a family history of breast cancer, especially those bereaved in adolescence, compared to women in the population, but evidence is inconsistent as to the impact of risk counselling on cancer worry. Unresolved grief or difficulties in adult relationships resulting from early bereavements may be highlighted by confronting a personal risk, and family relationships may be disrupted by the impact of breast cancer and bereavements, so that diffusing risk information can be problematic. With respect to risk management, women may have unrealistic expectations about the availability of pre-symptomatic genetic testing, and uptake of chemoprevention trials and risk-reducing mastectomies is low, so that women perceive a number of difficulties with these options. At risk women place high priority on access to regular mammographic

surveillance and, where appropriate, ovarian screening, but they may not be aware of the limitations of current screening methods. For high-risk women considering risk-reducing mastectomies, the trade off between risk reduction and personal issues such as body image and sexuality has to be carefully balanced, and pre-operative counselling and well-informed decision-making can help achieve favourable outcomes. For 100 women assessed in Manchester, cancer worries were highly significantly reduced and there were low levels of mental health problems and body image concerns in the first year after surgery. These findings appear to be stable over time, but one in six women, especially those experiencing short term or late complications, report negative changes in self image, or mood which require further assessment and, in some cases, psychological intervention. In summary, there are complex issues and risk management decisions facing women following risk communication, and continued access to information services and psychological care is essential.

473

INVITED

Hereditary breast and ovarian cancer: an advocate's viewpoint

F.E.G. Bach Kolling-Dandrieu. Meersel-Dreef, Belgium

Being in the chair of the Advocate support group for hereditary breast and ovarian cancer of the "BorstkankerVereniging Nederland" (BVN) I will discuss our work in general and, more specifically, I will dwell upon what we have accomplished so far and explain about the work that still remains to be done. At this moment the Advocate support group not only has established a phone help line but also a national network, which enables patients to exchange information on genetic testing and its consequences. Furthermore, the Advocate support group organizes seminars and represents the interests of patients at relevant meetings throughout *the country*.

It has been a little more than ten years since the discovery of the breast

and ovarian cancer genes BRCA1 and BRCA2 and it is likely that in future years more genes will be discovered in relation to many other diseases. Our experience in the Netherlands is that BRCA1 and BRCA2 gene mutations are often used as an example to start a debate on a multitude of questions relating to ethical issues. It is clear that we will be forced to take new attitudes towards many topics such as the patenting of human genes and insurance discrimination of gene mutation carriers. Also, we will have to change our views on ethical codes and have to decide how we are going to handle the knowledge that certain diseases are related to a specific genetic predisposition.

It is often argued that BRCA1 and BRCA2 mutation carriers should join their efforts in all European countries, because the hereditary breast and ovarian cancer group is considered a relatively small part of all the breast and ovarian cancer patients. It is indeed our position that we can all benefit from sharing mutual experiences, so we encourage and support cross-border co-operation and the exchange of information as much as possible. However, I dare to challenge the assumption that we are merely a small group of patients, since in the particular case of the genetically predisposed patient, the threat of cancer hangs over the entire family and therefore, the group of mutation carriers is in fact much larger than just the affected patients.

It can be concluded that we hope to find support through the Advocacy Channels of Europa Donna to accomplish more awareness in Europe for specific problems concerning hereditary breast and ovarian cancer. Secondly, it is of the utmost importance that specialists in the medical profession support us in order to improve the well-being of patients and their families. Furthermore, we should promote communication and exchange of data at various European Institutions on all levels with the ultimate goal to achieve some standardization of policies relating to genetics throughout Europe.

In this Genetics symposium we ask ourselves: where are we?

I would like to add this question: Genetic Advocates, where are YOU?